Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
Equipping Healthcare Professionals with the Necessary Tools for Improving Care in Ovarian Cancer
Choose from the criteria below to find an activity that fits you best.
Wednesday, May 18, 2022, 6:00 PM - 7:00 PM ET
Join us for this dynamic 1-hour CPE-certified live webinar, in which an expert pharmacist panel will discuss current guidance and emerging strategies for treating patients with early and advanced HCC. Sign up now!
The target audience for this activity is pharmacists, including clinical, managed care, and specialty pharmacists, who care for patients with HCC as well as other stakeholders in hematology/oncology practice.
Upon completion of this activity, the participant will be able to:
Courtney C. Cavalieri, PharmD, BCOP
Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
Amber Draper, PharmD, BCOP
Oncology Clinical Pharmacy Specialist
Clinical Coordinator, Oncology
Emory Healthcare Winship Cancer Institute
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-159-L01-P has been assigned to this live application-based activity (initial release date 5-18-22). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.
This activity is supported by an educational grant from AstraZeneca.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.